Publication: Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from thai patients and healthy adults
6
Issued Date
2008-05-01
Resource Type
ISSN
01251562
Other identifier(s)
2-s2.0-44949186546
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Southeast Asian Journal of Tropical Medicine and Public Health. Vol.39, No.3 (2008), 425-433
Suggested Citation
Pintip Pongpech, Penphun Naenna, Yupin Taipobsakul, Chanwit Tribuddharat, Somporn Srifuengfung Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from thai patients and healthy adults. Southeast Asian Journal of Tropical Medicine and Public Health. Vol.39, No.3 (2008), 425-433. Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/19682
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Prevalence of extended-spectrum beta-lactamase and class 1 integron integrase gene intl1 in Escherichia coli from thai patients and healthy adults
Other Contributor(s)
Abstract
Among 120 Escherichia coli isolates from Thai patients, 37 and 9 isolates were extended-spectrum beta-lactamase (ESBL) and suspected ESBL producers respectively while 5 E. coli isolates from 120 Thai healthy adults were suspected ESBL producers, lntegrase (intl1) gene was detected in 99% of the clinical and 87% of the non-clinical isolates. Among 37 ESBL producers, percent recovery of blaTEM, blaCTX-M, blaSHV and blaVEB was 78%, 78%, 8% and 8%, respectively. Twenty-five isolates of ESBL producers carried both blaTEM and blaCTX-M, 2 isolates carried 3 genes (blaTEM, blaCTX-M, and bla SHV) and 3 showed no detectable bla gene. Among the 14 suspected ESBL producers, intl1 and blaTEM were detected in 13 isolates. ESBL producers from clinical samples were resistant to most of the tested antimicrobial agents compared to non-ESBL producers and isolates from healthy adults with about half of the latter susceptible to all tested antimicrobial agents. Only one clinical isolate was resistant to imipenem. Susceptibility to trimethoprim/sulfamethoxazole among the clinical isolates in ESBL producer group (27%) and non-producer group (33%) were comparable, whereas the percent susceptibility of the non-clinical isolates was about twice that of the clinical isolates.